Login
$BMY
$62.93 +$0.00 (0.0%) After hours

$BMY 8-K SEC Filings

Filed On Filing
29 Oct 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Growth Portfolio Performance and Disciplined Execution Drive Strong Financial Results

30 Jul 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Strong Performance Underscores Growth Portfolio Momentum and Pipeline Progress

08 May 2026 8-K: Submission of Matters to a Vote of Security Holders
30 Apr 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Financial Results Reflect Strong Execution and a Strengthened Foundation with Significant Pipeline Milestones Ahead

05 Feb 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Financial results reflect disciplined execution and focus on delivering long-term growth

12 Jan 2026 8-K: Regulation FD Disclosure

1 Bristol Myers Squibb: Built for Growth 44th Annual J.P. Morgan Healthcare Conference Christopher Boerner, Ph.D., Board Chair & CEO January 12th, 2026

18 Nov 2025 8-K: Other Events

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol Myers Squibb”), today announced the accepted amounts and pricing terms of the previously announced tender offers to purchase for cash its outstanding n...

10 Nov 2025 8-K: Other Events

FIRST SUPPLEMENTAL INDENTURE, dated as of November 10, 2025 (the “First Supplemental Indenture”), among BMS Ireland Capital Funding Designated Activity Company, a designated activity company incorporated under the laws of Ireland (the “I...

03 Nov 2025 8-K: Other Events

(Princeton, N.J., November 3, 2025) – Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol Myers Squibb” or the “Offeror”), announced the commencement of tender offers (“Offers”) to purchase for cash certain of its outstanding notes (collec...

30 Oct 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Performance Marked by Continued Growth Portfolio Momentum, Pipeline Advancements and Strategic Business Development

31 Jul 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Performance Underscores Continued Execution Against Long-Term Growth Strategy

25 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

07 May 2025 8-K: Submission of Matters to a Vote of Security Holders
24 Apr 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution

18 Feb 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

06 Feb 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Performance Reflects Progress Toward Delivering Sustained, Top-Tier Growth

13 Jan 2025 8-K: Regulation FD Disclosure

43rd Annual J.P. Morgan Healthcare Conference January 13th, 2025 Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer

31 Oct 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Performance Reflects Continued Focus on Near-Term Execution and Building a Foundation for Long-Term Sustainable Growth

26 Jul 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Results Underscore Continued Progress on Commercial Execution, Driving the Growth Portfolio and Pipeline Advancement

18 Jun 2024 8-K: Departure/Election of Directors or Officers; Compensation

(Princeton, N.J., June 18, 2024) – Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected independent director Michael R. McMullen to the Board, effective July 1, 2024. Mr. McMullen will serve as a membe...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support